GSK and Vir Biotechnology Announce Continuing Progress of the COMET Clinical Development Program for Sotrovimab

– Analysis of final Day 29 data from COMET-ICE confirms sotrovimab significantly reduces 
hospitalization and risk of death in adults with mild-to-moderate COVID-19 who are at high risk 
of progression to severe disease –

– U.S. National Institutes of Health (NIH) COVID-19 Treatment Guidelines
updated to recommend use of sotrovimab –

– Further research initiated to evaluate intramuscular administration of sotrovimab for the
early treatment of mild-to-moderate COVID-19 in high-risk patients in a Phase 3 study –